EUCTR2013-003427-10-Outside-EU/EEA进行中（未招募）不适用
A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to Indian infants according to a 6-10-14 weeks and a 2-4-6 months schedule. - DTPA-HBV-IPV-119
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 214
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A male or female between, and including, 6 and 10 weeks of age at the time of the first vaccination.
- •Documented administration of a hepatitis B vaccine dose at birth.
- •Subjects who the investigator believes that their parent(s)/legally acceptable representatives can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- •Written informed consent obtained from the parents/LARs of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Born after a gestation period of at least 36 weeks.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 214
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Child in care.
- •Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone more than or equal to 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, or planned administration during the study period, with the exception of oral human rotavirus vaccination which is al-lowed at any time during the study.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib vaccination or disease, with the exception of a birth dose of hepatitis B vaccine and OPV as per local standard of care.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Family history of congenital or hereditary immunodefi-ciency.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •Acute disease and/or fever at the time of enrolment.
- •Fever is defined as temperature more than or equal to 37.5°C/99.5°F on oral, axillary or tympanic set-ting, or more than or equal to 38.0°C/100.4°F on rectal setting. The preferred route for recording temperature in this study will be oral/axillary.
- •Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
研究者
相似试验
招募中
3 期
A study to test the efficacy and safety in children of a vaccine developed by GlaxoSmithKline Biologicals for protection against multiple diseases, i.e. diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b.CTRI/2012/02/002399GlaxoSmithKline Biologicals224
进行中（未招募）
不适用
Immunogenicity and safety of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.EUCTR2012-004137-16-Outside-EU/EEAGlaxoSmithKline Biologicals454
进行中（未招募）
1 期
A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy - PRIMAAdvanced follicular lymphomaEUCTR2004-001756-36-GBGELA(RC)1,202
进行中（未招募）
1 期
Safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster (HZ) vaccine when administered under the skin (subcutaneously) vs. into a muscle (intramuscularly) in adults 50 years of age and older.Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults =50 years of age [YOA] and immunocompromised adults =18 YOA)MedDRA version: 14.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-005671-14-GBGlaxoSmithKline Biologicals1,082
进行中（未招募）
不适用
A randomised, multicentre, open-label, phase III study of neoadjuvantlapatinib, trastuzumab, and their combination plus paclitaxel in womenwith HER2/ErbB2 positive primary breast cancer - NeoALTTOWomen with primary ErbB2 overexpressing and/or gene amplified breast cancer > 2 cm diameter who have not undergone previous treatment for invasive breast cancerMedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2006-000564-81-GRGlaxoSmithKline Research and Development Limited450